Janssen Presents Longer-Term Talquetamab Follow-Up Data

Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination...

Related Keywords

Chicago ,Illinois ,United States ,Belgium ,Spain ,Salamanca ,Castillay Leóp ,Beerse ,Region Flamande ,American ,Talquetamab Monotherapy ,Maria Victoria Mateos ,Edmond Chan ,Chris Heuck ,Janssen Pharmaceutical Companies Of Johnson ,None Of The Janssen Pharmaceutical Companies ,American Society Of Clinical Oncology ,European Commission Grants Marketing Authorisation ,Companies Of Johnson ,American Cancer Society ,European Medicines Agency ,Exchange Commission ,Johnson ,University Hospital Of Salamanca ,Eastern Cooperative Oncology Group ,Janssen Biotech Inc ,Receptor Familyc Group ,Janssen Research Development ,American Society Of Hematology ,Janssen Pharmaceutical Companies ,Clinical Oncology ,Annual Meeting ,Senior Director ,Area Lead Haematology ,Humoral Immunity ,Evaluating Talquetamab ,Consultant Physician ,University Hospital ,Global Medical Head ,Janssen Research ,Part One ,Breakthrough Therapy Designation ,Orphan Drug Designation ,Janssen Biotech ,Pharmaceutical Companies ,Infectious Diseases ,Janssen Cilag Limited ,Private Securities Litigation Reform Act ,Janssen Pharmaceutica ,Janssen Pharmaceutical ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Refractory Multiple ,Patients With ,Refractory Multiple Myeloma ,Oral Presentation ,American Society ,Escalation Study ,Participants With Relapsed ,Subcutaneous Daratumumab Regimens ,Participants With Multiple ,Bispecific Antibody ,Teclistamab Each ,Combination With ,Programmed Cell Death ,Study Comparing Talquetamab ,Combination With Daratumumab ,Pomalidomide Versus Daratumumab ,Combination With Pomalidomide ,Participants With Multiple Myeloma ,Commission Grants Marketing Authorisation ,Subcutaneous Formulation ,Dexamethasone Versus Bortezomib ,Patients With Previously Treated Multiple Myeloma ,Three Year Follow Up ,Lymphoma Myeloma ,Today Population Factsheets ,Janssen Emea ,